Abstract

IntroductionAn independent meta-analysis; Pakpoor et al. Neurol Neuroimmunol Neuroinflamm 2015;2:e158) in Phase III trials (with a 2 year duration) of disease modifying drugs (DMDs) in patients with relapsing multiple sclerosis...

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Cladribine Tablets
  • Standardised Incidence Ratios
  • Cladribine Tablets In Patients
  • Incidence Of Malignancies
  • Matched Reference Population
    • + Show 5 more

Create a personalized feed of these topics

Get Started

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Similar Papers

The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study
  • Multiple Sclerosis Journal - Experimental, Translational and Clinical
  • Oct 9, 2017
Relevant
Not Relevant
Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis
  • Multiple Sclerosis and Related Disorders
  • Nov 1, 2020
Relevant
Not Relevant
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
  • Multiple Sclerosis and Related Disorders
  • Jan 1, 2022
Relevant
Not Relevant
067 Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies
  • Journal of Neurology, Neurosurgery & Psychiatry
  • May 15, 2018
Relevant
Not Relevant
Cladribine tablets added to IFN-β in active relapsing MS
  • Neurology - Neuroimmunology Neuroinflammation
  • Jul 11, 2018
Relevant
Not Relevant
Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice
  • Neurology, Neuropsychiatry, Psychosomatics
  • Aug 5, 2020
Relevant
Not Relevant
Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis
  • Clinical Drug Investigation
  • Jan 1, 2012
Relevant
Not Relevant
Cladribine Tablets: A Review in Relapsing MS
  • CNS Drugs
  • Aug 1, 2018
Relevant
Not Relevant
Economic Evaluation of Cladribine Tablets in Patients With High Disease Activity–Relapsing-Remitting Multiple Sclerosis in the Kingdom of Saudi Arabia
  • Value in Health Regional Issues
  • Sep 1, 2021
Relevant
Not Relevant
039 Rates of lymphopenia in years 1–4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets
  • Journal of Neurology, Neurosurgery & Psychiatry
  • May 15, 2018
Relevant
Not Relevant
POS0803 INCREASED RISK OF MALIGNANCY IN PATIENTS WITH TAKAYASU’S ARTERITIS: A POPULATION-BASED COHORT STUDY IN KOREA
  • May 23, 2022
Relevant
Not Relevant
MON-330 Cancer Incidence in 1,296 Patients with Acromegaly Is Not Increased: A Nationwide Population-Based Study
  • Journal of the Endocrine Society
  • May 8, 2020
Relevant
Not Relevant
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
  • Clinical Pharmacokinetics
  • Jul 10, 2018
Relevant
Not Relevant
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
  • Drugs
  • Nov 28, 2020
Relevant
Not Relevant
Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
  • Multiple Sclerosis Journal
  • Sep 5, 2017
Relevant
Not Relevant
READ MORE FROM

Journal of Neurology, Neurosurgery & Psychiatry

GPi-DBS-induced brain metabolic activation in cervical dystonia
Just Published
  • Journal of Neurology, Neurosurgery & Psychiatry
  • Sep 27, 2023
Relevant
Not Relevant
Dissociative seizures in the emergency room: room for improvement
Just Published
  • Journal of Neurology, Neurosurgery & Psychiatry
  • Sep 27, 2023
Relevant
Not Relevant
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study
Open Access
Just Published
  • Journal of Neurology, Neurosurgery & Psychiatry
  • Sep 25, 2023
Relevant
Not Relevant
Early treatment of type II SMA slows rate of progression of scoliosis
Just Published
  • Journal of Neurology, Neurosurgery & Psychiatry
  • Sep 22, 2023
Relevant
Not Relevant
Reduced long-term mortality after successful resective epilepsy surgery: a population-based study
Just Published
  • Journal of Neurology, Neurosurgery & Psychiatry
  • Sep 21, 2023
Relevant
Not Relevant
Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada’s population
Just Published
  • Journal of Neurology, Neurosurgery & Psychiatry
  • Sep 21, 2023
Relevant
Not Relevant
Comparative neural correlates of DBS and MRgFUS lesioning for tremor control in essential tremor
  • Journal of Neurology, Neurosurgery & Psychiatry
  • Sep 18, 2023
Relevant
Not Relevant
Correction: Efficacy of deep brain stimulation for treatment-resistant obsessive-compulsive disorder: systematic review and meta-analysis
  • Journal of Neurology, Neurosurgery & Psychiatry
  • Sep 14, 2023
Relevant
Not Relevant
Intraoperative physiology augments atlas-based data in awake deep brain stimulation
  • Journal of Neurology, Neurosurgery & Psychiatry
  • Sep 7, 2023
Relevant
Not Relevant
Cognitive and psychiatric outcomes in the GALAXY trial: effect of anaesthesia in deep brain stimulation
  • Journal of Neurology, Neurosurgery & Psychiatry
  • Sep 7, 2023
Relevant
Not Relevant